Development of a quantifiable symptom assessment tool for patients with chronic bronchitis: the Chronic Bronchitis Symptoms Assessment Scale.

COPD

Health Services Research and Development, VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, Washington 98108, USA.

Published: June 2005


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Clinical trials that rely solely on physiologic outcomes may underestimate effects of interventions on patients' symptoms and well-being. We sought to develop and validate an instrument to reliably assess symptom severity and frequency in therapeutic trials for patients with chronic bronchitis. We performed a series of psychometric studies that determined instrument content and assessed validity and reliability. The final version of the Chronic Bronchitis Symptoms Assessment Scale (CBSAS) comprised 15 scored items (16 items total). The instrument demonstrated strong reliability with moderate to high item correlations with total scores (0.41-0.80) and an overall Cronbach's alpha of 0.91. As expected, scores were at the bottom of the range for patients without a history of previous lung disease, and no ceiling effect was seen in the most severely obstructed patients. The CBSAS demonstrated statistically significant and moderate to strong association with spirometry, (post bronchodilator, % pred FEV1, r = -0.42, % pred FVC, r = -0.50), SGRQ (total, r = 0.67) and SOBQ (r = 0.50). The Chronic Bronchitis Symptoms Assessment Scale is an easy to administer, once daily or once weekly, valid and reliable outcome measure for assessing symptom severity among patients with chronic bronchitis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

chronic bronchitis
24
patients chronic
12
bronchitis symptoms
12
symptoms assessment
12
assessment scale
12
symptom severity
8
chronic
6
bronchitis
6
patients
5
development quantifiable
4

Similar Publications

Percutaneous Thoracic Duct Externalization and Autotransfusion in Patients With Lymphatic Failure Due to Elevated Central Venous Pressure.

Circ Cardiovasc Interv

September 2025

Division of Cardiology (Y.D., E.P., L.B., M.J.G., R.C., J.T., M.L.O.B., D.V., A.G.D.W., E.F., R.S., J.J.R., C.L.S.), Children's Hospital of Philadelphia, PA.

Background: External drainage of the thoracic duct can temporarily reduce tissue congestion and improve symptoms in patients with heart failure. However, loss of fluid limits the duration of this approach. Here, we report on our initial experience with thoracic duct drainage and autotransfusion in patients with elevated central venous pressure.

View Article and Find Full Text PDF

Background And Objectives: The impact of probable respiratory sarcopenia (RS) on the prevalence and incidence of chronic lung diseases (CLDs) in middle-aged and older adults remains poorly understood. This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) to explore this association.

Methods: A total of 6,614 participants aged 45 and above were included in a cross-sectional analysis in 2011, and 5,630 participants were followed for 7 years for longitudinal analysis.

View Article and Find Full Text PDF

Impact of bronchitis variability on outcomes of COPD.

BMJ Open Respir Res

September 2025

Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea

Objective: This study aimed to evaluate the impact of serial bronchitic status over two consecutive years on clinical outcomes, including frequency of exacerbation and lung function decline rate.

Methods: We analysed data from 1265 participants enrolled in the Korea COPD Subgroup Study, a nationwide prospective observational chronic obstructive pulmonary disease (COPD) cohort. Bronchitic status was determined using subquestionnaires of the COPD Assessment Test at baseline and after 1 year, classifying patients into three serial bronchitic groups of persistently not bronchitic (NB), intermittently bronchitic (IB) and chronic bronchitis (CB).

View Article and Find Full Text PDF

Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous condition characterized by diverse clinical phenotypes and underlying pathobiological mechanisms. Traditional "one-size-fits-all" management strategies have limited effectiveness in addressing this heterogeneity. The Treatable Traits (TTs) approach represents a precision medicine paradigm that targets specific, identifiable, and modifiable traits in individual patients, regardless of diagnostic labels.

View Article and Find Full Text PDF

Introduction: Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, is a major health concern in the U.S., with smoking as its leading risk factor.

View Article and Find Full Text PDF